Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Transplant rejection Stories

2013-11-21 13:04:03

Genomic analysis of transplant patients finds an opportunistic microorganism whose elevated presence could be used an indicator in treatment More than 260,000 Americans are alive today thanks to transplant operations that have replaced their failing kidneys, hearts, lungs or livers with healthy organs donated by volunteers or accident victims. But treatment doesn't end with surgery. Transplant recipients follow strict drug regimens designed to suppress their immune systems just enough...

2013-10-24 12:06:43

Discontinuing mycophenolate acid products does not seem to pose risks of transplant rejection Research suggests that fetal exposure to mycophenolic acid products (MPA)—which are drugs taken by transplant recipients to prevent rejection—may increase the risk of birth defects and spontaneous abortions. Results of this study will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA. To investigate these potential links, Serban...

2013-10-15 12:52:40

Researchers at the University of Illinois at Chicago have identified a protein expressed by human bone marrow stem cells that guides and stimulates the formation of blood vessels. Their findings, which could help improve the vascularization of engineered tissues, were reported online Oct. 12 in the Journal of Molecular and Cellular Cardiology. “Some stem cells actually have multiple jobs,” says Dr. Jalees Rehman, associate professor of cardiology and pharmacology at the UIC College...

2013-08-23 10:38:07

NIH-funded study provides more evidence supporting development of noninvasive tests Levels of a protein in the urine of kidney transplant recipients can distinguish those at low risk of developing kidney injury from those at high risk, a study suggests. The results also suggest that low levels of this protein, called CXCL9, can rule out rejection as a cause of kidney injury. The study appears online Aug. 22 in the American Journal of Transplantation. The work was funded by the National...

2013-06-27 12:28:21

- LCP-Tacro(TM), once-daily, demonstrated non-inferiority to Prograf®, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-Tacro(TM) 18.3%, Prograf® 19.6%) HORSHOLM, Denmark, June 27, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced LCP-Tacro(TM) successfully demonstrated non-inferiority compared to tacrolimus (Prograf(®); Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized,...

2013-06-06 12:26:32

Paper demonstrates potential for cow antibodies to treat human diseases LA JOLLA, Calif., June 6, 2013 /PRNewswire/ -- Fabrus Inc., a company developing a next-generation antibody discovery platform that expands the therapeutic applications of antibodies, today announced the publication of data in the journal Cell detailing a structural and sequence analysis of unusually long CDR3 antibodies from cows. Fabrus scientists were co-authors on the paper detailing results of work led by...

2013-05-21 16:27:48

HORSHOLM, Denmark, May 21, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014. For Investor and media contact: John Weinberg, M.D. EVP & Chief Commercial Officer Phone: +1 732...

2013-05-20 04:20:45

Data from the STRATO Study Presented at the 13th American Transplant Congress HORSHOLM, Denmark, May 20, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-Tacro(TM) to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO(TM) (STRATO) clinical trial, was presented at the 13(th) American...

2013-04-29 08:27:28

HORSHOLM, Denmark, April 29, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro Phase III 3001 study in stable kidney transplant patients and data from an extensive...

2013-04-22 16:24:00

LA JOLLA, Calif., April 22, 2013 /PRNewswire-USNewswire/ -- In a serendipitous discovery, scientists at The Scripps Research Institute (TSRI) have found a way to turn bone marrow stem cells directly into brain cells. Current techniques for turning patients' marrow cells into cells of some other desired type are relatively cumbersome, risky and effectively confined to the lab dish. The new finding points to the possibility of simpler and safer techniques. Cell therapies derived from...